ArticleJundishapur journal of microbiology2015
Antifungal Activity of Selenium Nanoparticles Synthesized by Bacillus species Msh-1 Against Aspergillus fumigatus and Candida albicans.
Article in Jundishapur journal of microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 125 citations in OpenAlex.
- Antifungal Efficacy of Selenium Microparticles Biosynthesized byFoods (Basel, Switzerland) · 2026Article
- Selenium nanoparticles: Eco-friendly synthesis, biological activities and biomedical applications - A comprehensive review.Materials today. Bio · 2026Review
- A novel solid-state approach for enhancing the antimicrobial and colorimetric properties of pine sawdust using selenium nanoparticles.Scientific reports · 2026Article
- Clove oil and selenium nanoparticles as eco-friendly antifungal agents for photographic preservation.Applied microbiology and biotechnology · 2026Article
- Therapeutic potential of greenly synthesized selenium nanoparticles against experimental cyclosporiasis.Scientific reports · 2025Article
- A novel clotrimazole selenium nano-composite for combating deep dermal Candida albicans infections and virulence genes.The Journal of antibiotics · 2025Article
- Screening of rhizobacteria from monkey pod trees for plant growth promoters and evaluating the antifungal potential of the biosynthesized selenium nanoparticles.Scientific reports · 2025Article
- Colistin-Conjugated Selenium Nanoparticles: A Dual-Action Strategy Against Drug-Resistant Infections and Cancer.Pharmaceutics · 2025Article
- Synthesis and Biomedical Based Applications of Selenium Nanoparticles: A Comprehensive Review.Indian journal of microbiology · 2025Article
- Nano Selenium: A Promising Solution for Infectious Diseases - Current Status and Future Prospects.Current pharmaceutical design · 2025Review
- Targeting Spore-Forming Bacteria: A Review on the Antimicrobial Potential of Selenium Nanoparticles.Foods (Basel, Switzerland) · 2024Review
- Selenium in Surgery.Cureus · 2024Review
- Alginate Extracted fromPolymers · 2024Article
- Anticandidal applications of selenium nanoparticles biosynthesized with Limosilactobacillus fermentum (OR553490).Discover nano · 2024Article
- In vitro assessment of the effect of magnetic fields on efficacy of biosynthesized selenium nanoparticles by Alborzia kermanshahica.BMC biotechnology · 2024Article
- PLGA and PDMS-basedFrontiers in pharmacology · 2024Article
- Article
- Antifungal screening of selenium nanoparticles biosynthesized by microcystin-producing Desmonostoc alborizicum.BMC biotechnology · 2023Article
- Antimicrobial Activity of Selenium Nanoparticles (SeNPs) against Potentially Pathogenic Oral Microorganisms: A Scoping Review.Pharmaceutics · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFungal infections affect various parts of the body and can be difficult to treat. Aspergillus infection causes a spectrum of diverse diseases particularly in lung according to host immunity. The two major entities are invasive pulmonary aspergillosis and chronic pulmonary aspergillosis. Candida infections can be superficial or invasive. Superficial infections often affect the skin or mucous membranes. However, invasive fungal infections are often life-threatening. Advances in nanotechnology have opened new horizons in nanomedicine, allowing the synthesis of nanoparticles that can be assembled into complex architectures. Novel studies and technologies are devoted to understanding the mechanisms of disease for the design of new drugs.
objectivesIn the present study, the antifungal activity of biogenic selenium nanoparticles (Se NPs) against Aspergillus fumigatus and Candida albicans was investigated. MATERIALS AND
methodsSe-reducing bacteria previously identified as Bacillus sp. MSh-1 were used for the intracellular biosynthesis of elemental Se NPs. The shape, size, and purity of the extracted NPs were determined with various instrumental techniques. The nanoparticles antifungal characterization mainly derives from the following pathways: (i) to generate sustained flux of nano-ions from the compounds that deposited on special substrates or imbedded in colloidal or semisolid matrices. (ii) To transport active those ions to sensitive targets on plasma membrane of fungi.
resultsThe results of energy-dispersive X-ray demonstrated that the purified NPs consisted of only Se. In addition, transmission electron micrographs showed that 120- to 140-nm spherical Se NPs were the most common. An antifungal assay was performed with a standard Clinical and Laboratory Standards Institute broth microdilution method. Minimum inhibitory concentration (MIC) measurements of the antifungal activity of the Se NPs against C. albicans (70 μg/mL) and A. fumigatus (100 μg/mL) showed that yeast cells were more sensitive than mold cells.
conclusionsThe MICs against A. fumigatus (100 μg/mL) and C. albicans (70 μg/mL) showed that biogenic Se NPs are useful antifungal agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.